fluorobenzenes has been researched along with Abdominal Obesity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrett, PH; Chan, DC; Meikle, PJ; Ng, TW; Ooi, EM; Watts, GF | 1 |
| Hu, M; Lee, MH; Mak, VW; Tomlinson, B | 1 |
1 trial(s) available for fluorobenzenes and Abdominal Obesity
| Article | Year |
|---|---|
Association of Plasma Ceramides and Sphingomyelin With VLDL apoB-100 Fractional Catabolic Rate Before and After Rosuvastatin Treatment.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Ceramides; Fluorobenzenes; Humans; Kinetics; Lipid Metabolism; Lipoproteins, VLDL; Male; Metabolic Syndrome; Metabolism; Middle Aged; Obesity, Abdominal; Pyrimidines; Rosuvastatin Calcium; Sphingomyelins; Sulfonamides | 2015 |
1 other study(ies) available for fluorobenzenes and Abdominal Obesity
| Article | Year |
|---|---|
Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily).
Topics: Aged; C-Reactive Protein; China; Cholesterol, HDL; Coronary Disease; DNA; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Nephelometry and Turbidimetry; Obesity, Abdominal; Polymorphism, Genetic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2010 |